预约演示
更新于：2025-12-29
Clofazimine
氯法齐明
更新于：2025-12-29
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C27H22Cl2N4 |
InChIKeyWDQPAMHFFCXSNU-UHFFFAOYSA-N |
CAS号2030-63-9 |
关联
64
项与 氯法齐明 相关的临床试验ChiCTR2500112822
An Exploratory Clinical Study on the Early Efficacy and Safety of JDB0131 Benzensulfonate Tablets in Patients with Multidrug-Resistant Tuberculosis
开始日期2025-11-20 |
申办/合作机构 北京威斯克生物医药科技有限公司 [+1] |
NCT07228702
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
开始日期2025-11-01 |
申办/合作机构 |
ChiCTR2500108732
A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets with Delamanid in Patients with Rifampin-resistant Tuberculosis (JD-RISE)
开始日期2025-09-10 |
申办/合作机构 首都医科大学附属北京胸科医院 [+2] |
100 项与 氯法齐明 相关的临床结果
登录后查看更多信息
100 项与 氯法齐明 相关的转化医学
登录后查看更多信息
100 项与 氯法齐明 相关的专利（医药）
登录后查看更多信息
2,156
项与 氯法齐明 相关的文献（医药）2026-01-01·LANCET INFECTIOUS DISEASES
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
Article
作者: Kanyama, Cecilia ; Lokande, Rahul ; Wambui Njorge, Anne ; Pradhan, Neeta ; Altman, Brooke ; Murtaugh, William ; Scarsi, Kimberly K ; Dorasamy, Afton ; Koele, Simon ; Mendoza-Ticona, Alberto ; Svensson, Elin M ; Du Plessis, Joan ; Weir, Isabelle ; Marc, Jean Bernard ; Svensson, Elin ; Koele, Simon E ; Meldrum, Jenna ; Metcalfe, John Z ; Van Grack, Austin ; Leon-Cruz, Jorge ; Clagett, Brian ; Yohane, Maxwell ; Knowles, Kevin ; Chaisson, Richard ; Goth, Melanie ; Maartens, Gary ; Haas, David ; Nevrekar, Neetal ; Weir, Isabelle R ; Hall, Luke ; Wei, Maria ; Beck, Justine ; Metcalfe, John ; Ntsalaze, Busisiwe ; Pierre, Samuel ; Rosania, Gus ; Scarsi, Kimberly ; Furin, Jennifer ; Samaneka, Wadzanai ; Kosashunhanan, Natthapol
BACKGROUND:
Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.
METHODS:
Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries. Participants aged 18 years or older with pulmonary tuberculosis who were sputum smear positive for acid-fast bacilli or molecular tuberculosis assay positive (with Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid) were eligible for enrolment. Individuals with HIV infection with a CD4+ cell count ≥100 cells per mm3 could participate. Participants were randomly assigned in a 2:1 ratio (group 1: group 2) or a 2:1:1 ratio (group 1: group 2: group 3), depending on consent to participate in the intensive pharmacokinetic visits required in group 3, using a central web-based system with permuted blocks. The group 1 regimen included 8 weeks of rifapentine-isoniazid-pyrazinamide-ethambutol-clofazimine, with a 2-week 300 mg clofazimine loading dose, followed by 5 weeks of rifapentine-isoniazid-pyrazinamide-clofazimine (13 weeks total). The group 2 control regimen included 8 weeks of isoniazid-rifampicin-pyrazinamide-ethambutol followed by 18 weeks of rifampicin-isoniazid. Group 3 was identical to group 1 over the first 4 weeks of treatment, except that the regimen was administered without a clofazimine loading dose (100 mg daily); after 4 weeks of group 3 treatment, participants transitioned to local standard of care to complete treatment. Group 3 was designed to assess the effect of a 2-week loading dose on clofazimine pharmacokinetics. Randomisation was stratified by HIV status and advanced disease on chest radiograph. The primary efficacy endpoint was time to sputum culture-negative status by 12 weeks. The primary safety endpoint was the proportion of participants experiencing any grade 3 or worse adverse event over 65 weeks. The key secondary endpoint was unfavourable clinical or bacteriological outcomes by week 65. The efficacy analysis population contained participants assigned to groups 1 and 2 who were not late exclusions (no positive culture at screening, entry, or week 1, or if rifampicin resistance or isoniazid resistance was detected at screening or entry); the safety analysis population contained all randomly assigned participants who took at least one dose of treatment. The trial was registered with ClinicalTrials.gov ID: NCT04311502.
FINDINGS:
104 participants were randomly assigned to group 1 (n=58), group 2 (n=31), and group 3 (n=15). 82 (79%) were male and 74 (71%) had radiographically advanced disease; 30 (29%) were people with HIV. The trial was stopped early for lack of clinical efficacy. For the primary efficacy outcome, 49 (89%) of 55 group 1 participants and 28 (90%) of 31 group 2 participants had stable sputum culture conversion by week 12 (adjusted hazard ratio 1·21 [90% CI 0·82-1·79]; p=0·2089). Adverse events grade 3 or worse occurred in 26 (45%) of 58 group 1 participants and five (16%) of 31 group 2 participants (difference 30%, 90% CI 14-45; p=0·002). The cumulative probability of a week 65 unfavourable outcome was 52% (95% CI 37-69) in group 1 versus 27% (14-50) in group 2 (p=0·049).
INTERPRETATION:
Although the trial was stopped early, we found that a 3-month regimen containing clofazimine and rifapentine had 12-week culture conversion rates that did not differ statistically from the standard of care. The regimen was associated with an unacceptably high proportion of participants with unfavourable composite clinical outcomes and grade 3 or worse adverse events.
FUNDING:
US National Institutes of Health Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) and the National Institute of Allergy and Infectious Diseases.
2025-12-31·European Clinical Respiratory Journal
The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and
Mycobacterium abscessus
pulmonary disease
Article
作者: Riddles, Timothy ; Evans, Ieuan E S ; Matson, Angela G ; Johnson, Ellie ; Mou, Claire Y ; Reid, David W ; Henderson, Daniel J ; Swenson, Rebecca ; Herd, Karen M ; McWhinney, Brett ; Burke, Andrew
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory Mycobacterium abscessus pulmonary disease. Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor. This case highlights the challenges surrounding ETI TDM in the context of acute severe illness, malnutrition, chronic infection, and drug-to-drug interactions. The marked clinical improvement seen, alongside sustained ETI plasma concentrations and suppressed sweat chloride levels on serial testing, provided reassurance of the use of ETI and rifabutin concomitantly in this case, and highlights the potential utility of TDM in helping guide clinical practice. Though a current barrier to the application of TDM includes ETI only being available as a fixed dose combination.
2025-12-10·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB
Article
作者: Kellermann, Tracy ; Wiesner, Lubbe ; Denti, Paolo ; Boeree, Martin J. ; Diacon, Andreas H. ; Aarnoutse, Rob ; Upton, Caryn M. ; McCulloch, Megan ; Calderin, Jose M.
ABSTRACT:
Tuberculous meningitis (TBM) treatment outcomes are poor, partly due to suboptimal drug penetration into the cerebrospinal fluid (CSF). Little is known about the CSF pharmacokinetics of many TB drugs, both established and new. This study investigated the CSF penetration of cycloserine (administered as terizidone) and clofazimine, two core second-line drugs for drug-resistant tuberculosis (TB). We recruited participants with pulmonary drug-resistant TB, but without TBM, receiving terizidone and/or clofazimine for at least 2 weeks and collected serial plasma samples and a single CSF sample. Drug concentrations were quantified with validated liquid chromatography-tandem mass spectrometry methods. Pharmacokinetic parameters were determined using noncompartmental analysis, and population pharmacokinetic modeling was used to estimate the partition coefficient and equilibration half-life. Data were available from 27 participants, with a median age of 36 (range 20–60) and a weight of 52 kg (30–73 kg), who contributed 216 plasma and 27 CSF samples. The plasma pharmacokinetics of both drugs was in line with previous reports. Terizidone, measured as cycloserine, achieved CSF exposure of 69% relative to plasma, with plasma and CSF concentrations equilibrating with a half-life of 4.7 hours. Clofazimine CSF penetration was 0.13% of plasma exposure, with an equilibration half-life of 55.4 hours. Cycloserine and clofazimine concentrations in CSF approximated their estimated unbound (active) concentration in plasma, thus suggesting good penetration of the unbound drug into the CSF, supporting their potential use in TBM regimens. This study demonstrates a feasible and reproducible method for effective assessment of CSF drug penetration for CNS infections.
74
项与 氯法齐明 相关的新闻（医药）2025-12-25
2025年，我国感染病学研究在多个关键领域取得突破性进展，充分展现了从基础研究到临床转化、从传统传染病应对到前沿技术攻关的全方位创新能力。
一是应对新发与再发传染病的科研响应体系日益敏捷与深刻，对病毒免疫机制的阐明，推动了下一代疫苗研发策略的革新，同时在疫情预警、溯源和防控策略优化方面也彰显了流行病学与多学科研究实力。二是前沿生物技术的驱动作用愈发显著。三是“以患者为中心”的临床研究导向更加明确。耐药结核全口服短程方案显著提升了治疗依从性与成功率；流感疫苗对心衰患者预后的改善研究，则将预防医学完美嵌入临床实践。四是自主创新药物研发迎来收获期。多款国产抗病毒新药的集中上市，打破了长期依赖进口的局面，为呼吸道感染疾病的防控提供了有力武器，保障了公共卫生安全的核心供给。这些工作不仅深刻回应了当下重大的公共卫生挑战，也为未来的学科发展指明了清晰路径。
展望未来，我们应继续强化基础研究与临床需求的对接，加速创新成果的普及与可及性，同时在全球合作中持续分享中国经验，共同构建人类卫生健康共同体。
肖永红 教授
01
新冠黏膜免疫机制
对人群防控意义重大
广州呼吸病全国重点实验室研究发现呼吸道黏膜中强效的SARS-CoV-2特异性T细胞有效对抗COVID-19并在患者肺部建立多功能组织驻留记忆。研究还发现肌内接种疫苗对诱导黏膜T细胞记忆效果有限，强调了开发呼吸道黏膜疫苗的重要性。（Nat Immunol.2025,26:459）
江苏省疾病预防与控制中心研究发现，新冠疫情期间的社交限制措施可能有效降低了青少年人群的 MTB 传播水平,为疫情对慢性呼吸道传染病传播的间接影响提供了关键流行病学证据。（Nat Commun.2025,16:9807）
02
HIV感染基因治疗、免疫重建与疫苗研发取得进展
武汉科技大学研发出EMT-Cas12a靶向基因疗法对活性复制期和潜伏休眠期HIV均能有效清除，且生物相容性高、毒性低，已通过医学伦理审查进入临床研究阶段。（Mol Ther.2025,S1525-0016:00949-9）
清华大学基础医学院与北京协和医院联合研究发现了HAART治疗后免疫无应答该机制,为理解艾滋病免疫重建不全的发病机制与开发更精准的干预策略提供了科学支持。（eBioMedicine.2025,115:105667）
中国疾病预防控制中心、北京协和医院联合研发国内首个复制型天坛痘苗载体HIV疫苗I期临床试验结果，可诱导持久的HIV特异性抗体与T细胞免疫应答。（Signal Transduct Target Ther.2025,10:208）
03
耐药结核全口服短程新方案发布
复旦大学附属华山医院历时5年完成全国多中心耐药结核病新型全口服短程疗法的临床研究TB-TRUST和TB-TRUST-plus，前者针对氟喹诺酮敏感的耐多药结核病，方案组成为左氧氟沙星、氯法齐明、环丝氨酸、利奈唑胺、吡嗪酰胺治疗6-9个月，新方案停药后1年无复发治疗成功率达到76.1%，较2020年世界卫生组织推荐的标准短程方案成功率提升13%。TB-TRUST-plus针对氟喹诺酮耐药的耐多药结核病患者，方案为6-9个月贝达喹啉、氯法齐明、环丝氨酸、利奈唑胺、吡嗪酰胺，最终研究结果显示新方案最终停药后1年无复发治疗成功率达到77.5%，将总疗程缩短至6-9个月。（Clin Microbiol Infect.2025,S1198-743X:00570-1）（Clin Infect Dis.2025:ciaf351）
04
重症肝病治疗新希望
空军军医大学西京医院完成世界首例六基因编辑猪人原位肝移植，解决了异种移植凝血-炎症-免疫三重障碍，为异种肝移植的临床应用奠定了基础，也为治疗急性肝功能衰竭或等待同种肝移植患者的生命维持提供了干预新思路。（Nature.2025,641:1029）
浙江大学医学院附属第一医院对HBV-ACLF患者外周血和肝穿组织进行单细胞多组学时序分析，首次绘制 ACLF 动态免疫病理图谱，发现一条“单核-巨噬-炎症中性粒细胞”主导的细胞因子风暴轴，为临床提供精准干预窗口。（Gut.2025年8月21日在线版）
05
生物人工肝研究I期临床研究成功
美国肝病学会年会发布一项中国多中心、开放标签首个生物人工肝系统（HepaCure）治疗I期临床试验结果，研究纳入多家三甲医院的慢加急性肝衰竭患者。所有受试者均完成治疗，成功率达100%。治疗后14天，患者肝功能呈现好转趋势，对下一步期临床研究奠定了基础。(AASLD 2025 Annual Meeting)
另一项中国科学院团队研究，完整阐述了将人原代肝细胞诱导为可增殖型肝细胞并实现体外大规模扩增的标准化流程。为生物人工肝提供稳定细胞来源、构建肝脏疾病模型及体外药物筛选平台。(Nat Protoc.2025,20:3722)
06
流感疫苗与群体免疫研究
再出成果
北京大学公共卫生学院采用生态学分析和队列研究的混合设计证实“免疫债”假说：疫情期间人群对流感病毒的暴露减少，可能导致后续对流感的易感性增加。研究呼吁在未来大流行中针对其潜在影响做好主动防范准备。（ Adv Sci.2025,12:e2410513）
由复旦大学和北京安贞医院等多家机构联合开展覆盖三个流感季的整群随机对照优效性试验，结果提示急性心力衰竭患者在住院期间接种流感疫苗，可改善其出院后12个月内的生存情况，并降低再住院风险。（Lancet.2025,406:1020）
07
我国本土基孔肯雅热
疫情传播与流行规律
广州医科大学团队通过标准化临床评估、病毒基因组测序及系统发育树重建以及2022~2025年高分辨率气候数据整合，揭示了中国华南地区佛山基孔肯雅病毒新发本地传播的流行特征，深入解析了疫情早期患者的临床表现、病毒演化特征及其关键突变，并评估了当地气候与环境条件对白纹伊蚊繁衍和病毒传播的促进作用，为理解本次疫情本土传播、完善监测预警体系以及强化临床识别提供了重要科学依据。（National Science Review.nwaf529）
08
2024年中国百日咳暴发
关键原因阐明
复旦大学团队通过2024年中国百日咳疫情暴发时五家哨点医院的14874例确诊病例研究，发现4-10岁学龄儿童占74.3%，近半数病例有疫苗接种史且90.7%为完全接种，突破性感染多见于7月龄以上儿童，家庭聚集性感染率达64%，婴儿重症风险最高，其中99.7%的分离菌株对阿奇霉素耐药。疫情的暴发的主要原因是人群对百日咳疫苗的保护力衰减，且以多抗性MT28克隆株为代表的非疫苗型ptxP3菌株流行。基于这些发现，团队提出需修订国家百日咳疫苗接种策略，为4-6岁儿童开展加强免疫，并调整一线抗菌药物治疗方案，以此应对未来防控挑战。（Lancet Reg Health West Pac.2025,60:101628）
09
中国鲍曼不动杆菌
流行与演变规律呈现
浙江大学联合北京大学研究，通过分析2011-2021年中国76家医院的1506株血流感染鲍曼不动杆菌分离株，发现国际克隆2型（IC2）占比约81.74%，为绝对优势株；优势序列型显著更替，ST208占比从2014年的12.93%升至2021年的21.19%，且其毒力、耐药性及干燥耐受性更强；研究还鉴定出149种序列型（含47种新类型）和101种荚膜分型，菌株多样性随时间提升，部分序列型（如ST540）具有中国地域特异性，为鲍曼不动杆菌血流感染防控策略优化提供关键依据。（Nat Commun.2025,16:3536）
10
多款国产抗呼吸道感染病毒药物上市应用
2025年我国多款创新抗流感病毒药物获批上市，为应对流感流行做好充分准备。新型流感病毒 RNA 聚合酶酸性蛋白（PA）抑制剂玛舒拉沙韦Ⅲ 期临床试验显示，与安慰剂相比，该药物使急性单纯性流感患者症状缓解中位时间较安慰剂组缩短20.3小时，退热时间显著缩短，用药1天内病毒载量下降更快。（Nat Med.2025,31:639）
同类药物玛硒洛沙韦研究发现，与安慰剂对照，玛硒洛沙韦使患者症状缓解时间缩短(48.4小时vs.62.9小时）。（Clin Microbiol Infect.2025,31:274）
第三款抗流感病毒药物昂拉地韦为RNA 聚合酶B2亚基抑制剂，临床研究与安慰剂比较，患者症状缓解时间缩短到38.83小时（安慰剂组63.35小时），安全性良好。（Lancet Respir Med.2025,13:597）
首都医科大学附属北京儿童医院针对 6 个月及以下住院 RSV 感染婴儿，开展RCT试验，结果显示，齐瑞索韦组第 3 天毛细支气管炎临床评分(WBCS)改善幅度显著优于安慰剂组，药物相关不良事件发生率略高（18% vs.11%），但无严重不良事件或死亡案例。（Lancet Child Adolesc Health.2025,9:325）
本文作者：中国医师协会感染科医师分会会长、浙江大学医学院附属第一医院传染病重症诊治全国重点实验室副主任 肖永红 教授
编辑/排版：裘佳
审核：许奉彦
【注】本文为医师报感染频道原创文章，禁止任何机构和个人私自转载或引用，如需转载，请联系授权。如未经允许转载或使用，本报将追究法律责任！
疫苗临床1期基因疗法临床结果免疫疗法
2025-12-21
·道道之道
2025年第51周（2025.12.14-2025.12.20）重要医学期刊论著更新如下：
1.综合期刊
LANCET
题目：Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
翻译：口服小分子胰高糖素样肽 - 1 受体激动剂奥福格列肽治疗2 型糖尿病合并肥胖症：ATTAIN-2Ⅲ期、双盲、随机、多中心、安慰剂对照临床试验
题目：Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
翻译：可切除及交界可切除Ⅰ-Ⅲ期胰腺导管腺癌术前改良氟尿嘧啶+ 亚叶酸钙+ 伊立替康+ 奥沙利铂方案（mFOLFIRINOX）对比帕博利珠单抗+ 白蛋白结合型紫杉醇+ 吉西他滨方案（PAXG）：PACT-21 CASSANDRA 随机、开放标签、2×2析因设计Ⅲ期临床试验首次随机分析结果
题目：Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial
翻译：吸入用甲氧氟烷、鼻用芬太尼与静脉用吗啡治疗挪威院前急性疼痛的疗效对比：PreMeFen随机、非劣效性、三臂Ⅲ期临床试验
题目：Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
翻译：异基因 CD19 嵌合抗原受体自然杀伤细胞（CAR-NK）疗法治疗系统性红斑狼疮的有效性与安全性：中国病例系列研究
NEW ENGLAND JOURNAL OF MEDICINE
题目：ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
翻译：循环肿瘤 DNA 指导的阿替利珠单抗辅助治疗肌层浸润性膀胱癌
题目：Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
翻译：替尔泊肽对比度拉糖肽治疗 2 型糖尿病的心血管结局
题目：Noninferiority of One HPV Vaccine Dose to Two Doses
翻译：人乳头瘤病毒疫苗单剂接种非劣效于两剂接种
题目：Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis
翻译：大剂量口服利福平治疗成人结核性脑膜炎的临床试验
BMJ-BRITISH MEDICAL JOURNAL
题目：Changes in hospital financial performance and quality of care after real estate investment trust acquisition
翻译：房地产投资信托基金收购后医院财务绩效与医疗质量的变化
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
题目：An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial
翻译：人工智能驱动的生活方式干预对比人工指导在糖尿病预防项目中的应用：一项随机临床试验
题目：Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score
翻译：序贯器官衰竭评估（SOFA）-2评分的建立与验证
题目：Arsenic Exposure Reduction and Chronic Disease Mortality
翻译：砷暴露水平降低与慢性病死亡风险的关联
NATURE MEDICINE
题目：Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
翻译：基于人工智能心电图的未确诊肝硬化筛查：一项务实性整群随机临床试验
LANCET DIGITAL HEALTH
题目：Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer
翻译：乳腺癌低标注量计算法肿瘤浸润淋巴细胞评估（ECTIL研究）：基于2340 例乳腺癌患者的多中心验证
题目：The impact of artificial intelligence-driven decision support on uncertain antimicrobial prescribing: a randomised, multimethod study
翻译：人工智能驱动决策支持系统对不确定性抗菌药物处方行为的影响：一项随机化多方法研究
题目：Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme in England
翻译：自动视网膜图像分析系统用于糖尿病视网膜病变分级分诊：一项英格兰大规模开放标签全国性筛查项目
题目：Efficacy of standalone smartphone apps for mental health: an updated systematic review and meta-analysis
翻译：独立智能手机心理健康应用程序的效能：一项更新的系统综述与荟萃分析
NPJ DIGITAL MEDICINE
题目：Interpretable deep learning for multicenter gastric cancer T staging from CT images
翻译：基于可解释性深度学习的多中心胃癌计算机断层扫描（CT）T分期评估
题目：Predicting Invasiveness of Lung Adenocarcinoma from Chest CT with Few-shot Vision-Language Ternary Classification Model
翻译：基于小样本视觉 - 语言三元分类模型的胸部CT 预测肺腺癌侵袭性
题目：The structure-preserving spectral graph neural network for dual kinase inhibitors and synergy scoring in gastric cancer
翻译：用于胃癌双激酶抑制剂筛选及协同评分的结构保留谱图神经网络
题目：Bridging clinical knowledge and AI: an interpretable transformer framework for ECG diagnosis
翻译：融合临床知识与人工智能：一种用于心电图诊断的可解释性Transformer 框架
题目：RMS: a ML-based system for ICU respiratory monitoring and resource planning
翻译：RMS 系统：基于机器学习的重症监护病房（ICU）呼吸监测与资源规划系统
题目：Systematic review and meta-analysis of regulator-approved deep learning systems for fundus diabetic retinopathy detections
翻译：监管机构批准的深度学习眼底糖尿病视网膜病变检测系统的系统综述与荟萃分析
题目：An AI-powered tongue image model for home-based monitoring of liver fibrosis
翻译：基于人工智能舌象模型的居家肝纤维化监测
题目：Artificial intelligence-driven multivariate integration for pulmonary arterial pressure prediction in pulmonary hypertension
翻译：人工智能驱动的多变量整合模型预测肺动脉高压患者肺动脉压力
题目：Effects of app delivered self hypnosis on stress management
翻译：应用程序介导的自我催眠对压力管理的效果
题目：An Automated Classifier of Harmful Brain Activities for Clinical Usage Based on a Vision-Inspired Pre-trained Framework
翻译：基于视觉启发预训练框架的临床用有害脑电活动自动分类器
2.肿瘤学
CA-A CANCER JOURNAL FOR CLINICIANS
题目：Bridging the cancer divide: Policy and structural solutions for equity in the United States
翻译：弥合癌症医疗鸿沟：美国实现医疗公平的政策与结构性解决方案
ANNALS OF ONCOLOGY
题目：Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
翻译：卡匹沙替尼联合紫杉醇一线治疗转移性三阴性乳腺癌：全球多中心Ⅲ期随机对照CAPItello-290 试验结果
题目：The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test
翻译：晚期前列腺癌精准靶向 AKT 治疗的阿喀琉斯之踵：检测方法限制治疗潜力发挥
题目：Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
翻译：局限性及局部区域性前列腺癌：欧洲肿瘤内科学会（ESMO）诊断、治疗与随访临床实践指南
题目：Germline alterations in patients with lung cancer
翻译：肺癌患者的胚系基因变异特征
题目：Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple Institutions
翻译：新一代多中心研究：基于人工智能自动化处理多中心肺癌患者非结构化健康医疗记录
JOURNAL OF CLINICAL ONCOLOGY
题目：Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
翻译：三阴性乳腺癌新辅助化疗在紫杉类 - 蒽环类序贯方案基础上加用卡铂的疗效：一项Ⅲ期随机对照试验
题目：Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial
翻译：新辅助药物 TQB2102 治疗局部晚期或早期人表皮生长因子受体2 阳性乳腺癌的有效性与安全性：一项随机、开放标签、多中心Ⅱ期试验
题目：Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
翻译：共识分子亚型作为 RAS 野生型转移性结直肠癌一线治疗生物标志物的个体患者数据荟萃分析
题目：Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study
翻译：奎扎替尼治疗初诊 FLT3 基因内部串联重复阴性急性髓系白血病：随机、双盲、安慰剂对照Ⅱ期QUIWI 研究
题目：Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
翻译：阿米万他单抗联合拉泽替尼治疗罕见表皮生长因子受体（EGFR）突变晚期非小细胞肺癌：CHRYSALIS-2研究结果
LANCET ONCOLOGY（本周无更新）
NATURE CANCER（本周无更新）
JAMA ONCOLOGY
题目：Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial
翻译：前列腺特异性膜抗原正电子发射断层显像引导的前列腺癌根治术后挽救性放疗剂量强化：一项Ⅱ期随机临床试验
题目：The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials
翻译：结肠癌治愈的定义界定：基于 15 项随机临床试验的汇总分析
题目：Risk Factors for Valvulopathy Among Childhood Cancer Survivors
翻译：儿童癌症幸存者心脏瓣膜病的危险因素
题目：Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
翻译：致病性基因变异、家族史与美国女性乳腺癌的累积发病风险
题目：Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma
翻译：人工智能检测的肿瘤浸润淋巴细胞与程序性死亡受体1（PD-1）抑制剂治疗黑色素瘤的预后关联
题目：Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment
翻译：乳腺癌治疗后心力衰竭或心肌病发病风险预测模型
题目：Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality
翻译：坚持遵循体力活动指南与消化系统癌症发病及死亡风险的关联
题目：Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women
翻译：激素避孕药剂型与青少年及绝经前女性乳腺癌发病风险
CANCER RESEARCH
题目：The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer
翻译：脯氨酰异构酶 PIN1 调控胰腺癌成纤维细胞分化状态及细胞间互作
题目：Interaction and Reciprocal Stabilization of H3.3 and PARP1 Promote DNA Damage Repair and Tumor Progression in Small Cell Lung Cancer
翻译：H3.3 与PARP1 的相互作用及双向稳定促进小细胞肺癌DNA 损伤修复与肿瘤进展
题目：The Microbial Bile Acid Metabolite 3-Oxo-LCA Inhibits Colorectal Cancer Progression
翻译：微生物胆汁酸代谢产物 3 - 氧代- 石胆酸抑制结直肠癌进展
题目：Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma
翻译：巨噬细胞与肿瘤共进化的细胞类型特异性定量免疫肽组分析揭示胶质母细胞瘤的治疗性MHC-Ⅰ类分子结合肽
题目：circADAMTS12 Inhibits the Antitumor Activity of Microglia to Enable Metastatic Colonization in the Brain
翻译：环状 RNA ADAMTS12 抑制小胶质细胞抗肿瘤活性以促进结肠癌脑转移定植
题目：Surgery-Induced Neutrophil Extracellular Traps Promote Tumor Metastasis by Reprogramming Cancer Cell Lipid Metabolism
翻译：手术诱导的中性粒细胞胞外陷阱通过重编程癌细胞脂质代谢促进肿瘤转移
题目：An Olive Oil–Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer
翻译：橄榄油基高脂饮食促进肥胖相关三阴性乳腺癌转移
题目：Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity
翻译：帕金蛋白诱导高迁移率族蛋白 B1 泛素化及大细胞外囊泡释放以激活抗肿瘤免疫
题目：Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
翻译：抑制 GSK3 与TSC2 介导AKT 在肝细胞癌中的促癌活性
题目：Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
翻译：弥漫大 B 细胞淋巴瘤患者治疗前外周血中独特的细胞与分子特征与嵌合抗原受体T 细胞（CAR-T）治疗疗效相关
题目：Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics
翻译：导管原位癌中空间非连续的突变图谱揭示非竞争性生长动力学特征
题目：Path2Omics Enhances Transcriptomic and Methylation Prediction Accuracy from Tumor Histopathology
翻译：Path2Omics 工具基于肿瘤组织病理学特征提升转录组与甲基化预测精度
题目：Mathematical Modeling Quantifies “Just-Right” APC Inactivation for Colorectal Cancer Initiation
翻译：数学建模量化结直肠癌发生过程中腺瘤性息肉病基因（APC）的“适度”失活效应
题目：Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
翻译：人工智能与多模态数据整合解析胃癌三级淋巴结构成熟度
题目：Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
翻译：大规模 T 细胞受体库测序揭示用于诊断性质待定肺结节的肿瘤特异性信号
CLINICAL CANCER RESEARCH
题目：Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
翻译：伊布替尼治疗慢性淋巴细胞白血病患者中联合伊纳鲁单抗（VAY736）的疗效：一项Ⅰb期研究结果
题目：Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
翻译：细胞外基质 - 髓源性癌症相关成纤维细胞特征与HPV 阳性头颈部鳞状细胞癌患者对度伐利尤单抗联合二甲双胍新辅助程序性死亡配体1（PD-L1）免疫检查点抑制剂治疗耐药相关
题目：Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
翻译：循环肿瘤细胞在浸润性小叶乳腺癌中的预后意义及预测价值——STIC CTC 试验的探索性分析
题目：ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
翻译：局部晚期直肠癌全程新辅助治疗及非手术治疗期间循环肿瘤DNA 的纵向分析：NOMINATE试验的生物标志物研究
题目：LRP1bLoss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial
翻译：LRP1b基因缺失预测非小细胞肺癌患者对免疫治疗的敏感性：Ⅲ期CheckMate-026 随机试验分析
题目：Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence
翻译：前列腺癌外照射放疗前的放射基因组学分析发现转化生长因子-β（TGF-β）活性相关转录组特征驱动肿瘤复发
题目：Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma
翻译：肿瘤微小 RNA 特征与Ⅱ/Ⅲ期黑色素瘤患者预后相关
题目：Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET
翻译：基于磷脂酰肌醇蛋白聚糖 3 靶向单域抗体正电子发射断层显像的肝癌诊断及疗效监测
题目：Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
翻译：以黏蛋白 1-C 抗体- 药物偶联物靶向治疗对KRAS 抑制剂耐药的胰腺癌
题目：Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
翻译：新型叶酸受体α靶向拓扑异构酶1 抑制剂偶联抗体药物AZD5335 的研发：用于治疗叶酸受体α阳性癌症
题目：D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
翻译：靶向 D3 - 神经节苷脂- 神经母细胞瘤癌基因同源物2 的嵌合抗原受体T 细胞在神经母细胞瘤及小细胞肺癌临床前模型中兼具安全性与有效性
题目：The Impact of JAK1Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer
翻译：JAK1致病性基因变异及主要组织相容性复合体Ⅰ类分子表达对子宫内膜癌患者免疫检查点抑制剂治疗应答的影响
题目：Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
翻译：雌激素受体低表达转移性乳腺癌的预后及生物学特征：一项多中心队列研究与TONIC 试验结果
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新）
3.内分泌学与代谢
LANCET DIABETES & ENDOCRINOLOGY（本周无更新）
4.呼吸病学
LANCET RESPIRATORY MEDICINE（本周无更新）
5.心血管病学
EUROPEAN HEART JOURNAL
题目：Atrial fibrillation in former world-class rowers: role of environmental and genetic factors
翻译：前世界级赛艇运动员的心房颤动：环境与遗传因素的作用
题目：Hypokalaemia and atrial fibrillation detected by implanted loop recorders
翻译：植入式循环记录仪检出的低钾血症与心房颤动
题目：Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study
翻译：一过性抗胆碱能药物负荷与院外心脏骤停的关联性：一项病例交叉研究
题目：Circadian patterns of atrial fibrillation and disease progression assessed by implanted loop recorders
翻译：基于植入式循环记录仪评估心房颤动的昼夜节律模式及疾病进展
题目：Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging
翻译：心房颤动与动脉粥样硬化在磁共振成像中所致脑血管病变的差异特征
CIRCULATION
题目：Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
翻译：氧化磷脂、脂蛋白（a）与急性冠状动脉综合征患者的心血管结局
题目：Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade
翻译：利用遗传替代标志物探究终身心脏钠通道阻滞的效应
题目：High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial
翻译：高压局灶性脉冲电场消融治疗瘢痕相关性室性心动过速：首个人体VCAS 试验
题目：Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy
翻译：心肌过度收缩与氧化应激导致肥厚型心肌病患者肌酸激酶功能异常
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（本周无更新）
6.传染病学
LANCET INFECTIOUS DISEASES
题目：Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
翻译：新冠疫情后美国儿童地方性病毒再流行的动态变化（2022—2023年）：一项前瞻性、多中心、纵向免疫流行病学监测研究
题目：Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
翻译：索托维单抗对比常规治疗用于新冠病毒感染住院患者的疗效：RECOVERY随机、对照、开放标签平台试验
题目：A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
翻译：含氯法齐明 - 利福喷丁的3 个月方案治疗药物敏感性结核病与标准治疗的对比：Clo-Fast随机、开放标签2c 期临床试验
题目：Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
翻译：2021—2022年全球应对抗菌药物耐药性的政策措施：一项覆盖161 个国家和地区的系统性治理分析
题目：Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
翻译：蒿甲醚 - 苯芴醇、青蒿琥酯- 阿莫地喹、双氢青蒿素- 哌喹及青蒿琥酯- 咯萘啶治疗乌干达6 月龄至10 岁儿童无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签4 期临床试验
题目：Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
翻译：辐射减毒全子孢子疟疾疫苗在加蓬儿童中的安全性、耐受性及保护效力：一项随机、双盲、安慰剂对照2 期试验
题目：Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
翻译：TAK-003 登革热疫苗在2024 年巴西圣保罗登革热疫情中对青少年的保护效果：一项阴性病例对照研究
题目：Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
翻译：利福舒替尼三联疗法对比铋剂联合克拉霉素三联疗法一线治疗中国幽门螺杆菌感染：EVEREST-HPⅢ期、多中心、随机、三模拟、双盲、对照、非劣效性试验
CLINICAL MICROBIOLOGY AND INFECTION
题目：Penicillin V as first-line treatment of pneumonia in primary care: a registry-based study
翻译：青霉素 V 作为基层医疗机构肺炎一线治疗方案的疗效：一项基于登记数据库的研究
题目：Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults
翻译：迈向静脉用利奈唑胺的模型指导精准给药：针对危重症成人患者药代动力学模型的多中心外部验证
题目：Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland
翻译：Xpert MTB/RIF Ultra 检测在肺部及肺外标本中的诊断效能：芬兰低发病率地区的回顾性评价
题目：Defining epidemiological cutoff values for Brucella melitensis: an European multicentre study
翻译：羊布鲁氏菌流行病学折点的界定：一项欧洲多中心研究
题目：In vitroactivity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020)
翻译：舒巴坦 / 杜洛巴坦对中国鲍曼不动杆菌临床分离株的体外抗菌活性及耐药机制研究（2019—2020年）
题目：Complex pathways to ceftolozane-tazobactam resistance in clinical Pseudomonas aeruginosaisolates: a genomic epidemiology study
翻译：铜绿假单胞菌临床分离株对头孢洛扎 - 他唑巴坦耐药的复杂通路解析：一项基因组流行病学研究
题目：Frailty predicts in-hospital and 1-year outcomes in patients with infective endocarditis
翻译：衰弱状态对感染性心内膜炎患者住院期及1 年预后的预测价值
题目：Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multicentre, randomized, double-blind, placebo-controlled, phase 3 clinical trial
翻译：国产减毒活带状疱疹疫苗在中国 40 岁及以上健康成人中的有效性与安全性：一项多中心、随机、双盲、安慰剂对照Ⅲ期临床试验
题目：Current situation of solid organ transplantation from HIV-positive donors to HIV-positive recipients in Europe: the Spanish perspective
翻译：欧洲 HIV 阳性供体向HIV 阳性受体开展实体器官移植的现状：西班牙视角
题目：The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial
翻译：奥密克戎流行期间瑞德西韦与奈玛特韦/ 利托那韦对新冠病毒感染住院患者死亡率的影响：一项仿真目标试验
题目：Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine
翻译：初治 HIV-1 感染者接受多替拉韦/ 拉米夫定方案与多替拉韦联合丙酚替诺福韦/ 恩曲他滨方案治疗后，病毒储存库及炎症水平的纵向评估：一项随机临床试验
题目：Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study
翻译：佐剂呼吸道合胞病毒疫苗在高危移植受者中的安全性与免疫原性：一项干预性队列研究
题目：Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial
翻译：晚期 HIV 感染者接受多替拉韦方案与达芦那韦为基础的三联抗逆转录病毒治疗的免疫重建效果对比：Advanz-4随机临床试验
7.胃肠肝病学
LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新）
JOURNAL OF HEPATOLOGY
题目：Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States
翻译：健康饮食与规律运动可显著降低美国不同性别人群中酒精归因性肝脏疾病死亡率
题目：Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation
翻译：CIDEB基因体细胞功能缺失突变通过增强脂解作用与脂肪酸氧化减轻肝脏脂肪变性
题目：Enhanced surveillance, subtyping, and host adaptation analysis reveal genotype-wide zoonotic potential of rat hepatitis E virus
翻译：强化监测、亚型分析及宿主适应性研究揭示鼠戊型肝炎病毒全基因型的人畜共患病潜在风险
题目：Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells
翻译：工程化单克隆抗体托贝韦巴特增强 Fc 受体阳性细胞对乙肝表面抗原的捕获并激活乙肝病毒特异性T 细胞
题目：Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
翻译：依折麦布醇治疗原发性硬化性胆管炎的安全性与有效性：ELMWOODⅡ期随机对照试验
题目：Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1integrin inhibitor, in primary sclerosing cholangitis
翻译：αvβ6/αvβ1整合素抑制剂贝索替格拉斯特治疗原发性硬化性胆管炎的Ⅱ期INTEGRIS-PSC 试验
题目：Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis
翻译：受体相互作用蛋白激酶 3（RIPK3）作为预测肝硬化急性失代偿患者预后的新型生物标志物的鉴定与验证
题目：Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
翻译：ADP-A2AFP TCR-T 细胞疗法治疗晚期肝细胞癌或胃肝样腺癌的Ⅰ期临床试验
题目：Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma
翻译：蛋白质基因组学图谱预测肝外胆管癌辅助化疗的疗效
题目：Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease
翻译：患者来源肝类器官可重现肝脏上皮细胞异质性，为酒精相关性肝病提供精准建模工具
题目：Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma
翻译：通过亮氨酸激活的亮氨酰 - tRNA 合成酶1 恢复N - 糖基化，逆转肝内胆管癌的化疗耐药性
题目：Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels
翻译：LONP1 表达下调通过升高乳清酸水平加重代谢相关脂肪性肝炎（MASH）诱导的肝纤维化
GASTROENTEROLOGY
题目：Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation
翻译：影响组蛋白乙酰化的化学扰动调控结直肠癌分化进程
题目：Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis
翻译：选择性尿激酶抑制联合化疗：通过增强抗肿瘤免疫与减少转移治疗胰腺癌的新策略
题目：Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study
翻译：血糖定义的新发糖尿病患者胰腺癌发病风险：一项前瞻性队列研究
题目：Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC
翻译：英夫利昔单抗早期血药浓度及清除率预测重症急性溃疡性结肠炎英夫利昔单抗挽救治疗的疗效：PREDICT-UC研究结果
题目：Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Improves Colonic Barrier Function and Mast Cell Activation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Mechanistic Trial
翻译：低可发酵低聚糖、双糖、单糖及多元醇饮食改善腹泻型肠易激综合征患者结肠屏障功能与肥大细胞活化：一项机制性试验
题目：Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation
翻译：机器学习模型提升全球肝硬化前瞻性队列患者住院死亡风险预测效能及外部验证
题目：A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study
翻译：内镜黏膜下剥离术对比经肛微创手术治疗早期直肠肿瘤的随机对照试验：DSETAMIS-2018研究
题目：GastroNet-5M: A Multicenter Dataset for Developing Foundation Models in Gastrointestinal Endoscopy
翻译：GastroNet-5M 数据集：用于开发胃肠内镜基础模型的多中心数据集
题目：The Natural History of Gastroesophageal Varices in Children With Portal Hypertension
翻译：门静脉高压症儿童患者食管胃底静脉曲张的自然病程研究
GUT
题目：Circulating HBV RNA and HBsAg seroconversion in patients with chronic HBV infection: a long-term follow-up study starting from childhood in Taiwan
翻译：中国台湾地区慢性乙型肝炎病毒感染患者循环乙肝病毒RNA 与乙肝表面抗原血清学转换：一项始于儿童期的长期随访研究
题目：Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal
翻译：停药诱导乙型肝炎感染状态扰动过程中B 细胞免疫功能的动态监测
题目：Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis
翻译：遗传性慢性胰腺炎诱导的细胞可塑性与突变型Kras 协同促进胰腺癌早期发生
题目：Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer
翻译：肠道细菌产生的次级胆汁酸促进西式饮食相关结直肠癌的发生发展
题目：Effects of a probiotic fermented dairy product on hippocampal metabolites, structure and function: an 8-week randomised, placebo-controlled trial in healthy women
翻译：益生菌发酵乳制品对健康女性海马代谢物、结构及功能的影响：一项8 周随机安慰剂对照试验
题目：PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction
翻译：磷酸烯醇式丙酮酸羧激酶 1（PCK1）缺失通过12 - 羟基二十碳四烯酸（12-HETE）诱导的CD8⁺ T 细胞功能障碍促进代谢相关脂肪性肝炎相关肝细胞癌（MASH-HCC）进展
HEPATOLOGY
题目：Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study
翻译：基于血清 N - 糖组学分析的慢性乙型肝炎患者肝细胞癌早期筛查、诊断及复发监测：一项队列研究
题目：Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma
翻译：空间单细胞蛋白质组图谱解析肝内胆管癌的肿瘤微环境生态系统
题目：Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients
翻译：免疫耐受期患者乙肝表面抗原（HBsAg）高水平与肝细胞癌（HCC）发病延迟相关
题目：Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection
翻译：乙肝 e 抗原（HBeAg）阴性不确定期患者相比HBeAg 阴性慢性感染期患者肝细胞癌发病风险升高
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
题目：Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects
翻译：基于高分辨率阻抗测压的环咽肌功能障碍诊断及与健康对照者的对比研究
题目：Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States
翻译：美国大规模多样化人群中幽门螺杆菌经验性治疗的疗效对比
题目：Long-Term Mortality After Cholecystectomy in a Nationwide Cohort of Swedish Individuals Between 1969 and 2016
翻译：瑞典全国队列研究：1969—2016年胆囊切除术患者的远期死亡率分析
题目：Nasal Continuous Positive Airway Pressure to Reduce Hypoxia in Patients With Obesity Undergoing Sedated Upper Gastrointestinal Endoscopy: A Prospective Randomized Trial
翻译：经鼻持续气道正压通气改善肥胖患者镇静状态下上消化道内镜检查的缺氧状况：一项前瞻性随机试验
题目：Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B
翻译：代谢合并症与慢性乙型肝炎患者肝纤维化严重程度及纤维化逆转的相关性
题目：The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis
翻译：血管升压素生物标志物和肽素与全身炎症相关，并可优化失代偿期肝硬化患者的预后评估
题目：Transferrin Saturation and Serum Ferritin Are Main Predictors of Liver Iron Content in Subjects With Hyperferritinemia
翻译：转铁蛋白饱和度与血清铁蛋白是高铁蛋白血症患者肝脏铁含量的主要预测指标
题目：Microbiological Profile of Bacterial Infections in Patients With Cirrhosis Over Time: A 20-year Territory-wide Study
翻译：肝硬化患者细菌感染的病原谱变迁：一项为期20 年的全区域研究
题目：Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial
翻译：6mm 与8mm 经颈静脉肝内门体分流术治疗食管胃底静脉曲张破裂出血的疗效对比：一项随机对照试验
题目：Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease
翻译：英夫利昔单抗对比乌司奴单抗治疗初治生物制剂的克罗恩病患者内镜下及透壁缓解的疗效
题目：Liver Transplantation Is Associated With a Reduced Risk of Colorectal Dysplasia in Patients With IBD and Concomitant PSC
翻译：肝移植可降低炎症性肠病合并原发性硬化性胆管炎患者的结直肠异型增生风险
题目：Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: A TOpClass Global Expert Delphi Consensus
翻译：肛周瘘管型克罗恩病影像学愈合标准的界定：TOpClass全球专家德尔菲共识
题目：Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab
翻译：英夫利昔单抗治疗儿童克罗恩病时，主动药物浓度监测对比临床经验给药对内镜下愈合的影响
题目：Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity
翻译：依曲莫德治疗溃疡性结肠炎的疗效：基于基线内镜严重程度分层的ELEVATE UC 52 与ELEVATE UC 12 研究分析
题目：Symptoms of Constipation: Relationship Between Questionnaires and Diaries and Impact on Quality of Life
翻译：便秘症状：问卷与日记记录的一致性及其对生活质量的影响
题目：Multicenter Validation of Video-based Deep Learning to Evaluate Defecation Patterns on 3-dimensional High-definition Anorectal Manometry
翻译：基于视频的深度学习评估三维高分辨率肛门直肠测压排便模式的多中心验证
题目：Performance of a Smartphone-based Stool Test for Use in Colorectal Cancer Screening: Population-based Study
翻译：基于智能手机的粪便检测用于结直肠癌筛查的效能：一项人群研究
8.公共卫生和流行病学
LANCET PUBLIC HEALTH（本周无更新）
LANCET PLANETARY HEALTH（本周无更新）
LANCET GLOBAL HEALTH（本周无更新）
9.微生物学
FUNGAL DIVERSITY（本周无更新）
LANCET MICROBE（本周无更新）
NATURE MICROBIOLOGY
题目：A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice
翻译：疟原虫来源纳米颗粒疫苗诱导小鼠产生抗疟疾无菌保护作用
题目：Pneumococcal S protein coordinates cell wall modification and repair to resist host antimicrobials
翻译：肺炎链球菌 S 蛋白协同调控细胞壁修饰与修复以抵抗宿主抗菌防御
题目：Streptococcus pneumoniaeS protein activates PBP1a to regulate peptidoglycan remodelling and cell division
翻译：肺炎链球菌 S 蛋白激活青霉素结合蛋白1a（PBP1a）调控肽聚糖重塑与细胞分裂
题目：Zoonotic Streptococcusimports glucose to inhibit stringent response and promote growth during meningitis
翻译：人畜共患链球菌摄取葡萄糖以抑制严紧反应并促进脑膜炎发病期的菌株增殖
MICROBIOME
题目：Bacillus amyloliquefaciens PP19 regulation of microbial communities and suppression of Peronophythora litchii
翻译：解淀粉芽孢杆菌 PP19 对微生物群落的调控作用及对荔枝霜疫霉菌的抑制效果
题目：Sodium butyrate modulates ocular surface microbiome and attenuates inflammation of meibomian gland dysfunction in ApoE−/− mice
翻译：丁酸钠调控载脂蛋白 E 基因敲除（ApoE⁻/⁻）小鼠眼表微生物组并减轻睑板腺功能障碍相关炎症
题目：Synthetic microbial community in pristine environment promotes the growth of the endangered plant Lilium tsingtauense
翻译：原生环境合成微生物群落促进珍稀濒危植物青岛百合生长
题目：Gut microbiome-derived indole-3-carboxaldehyde promotes intestinal development via AHR-NRF2 signaling in the early-life of chicks
翻译：雏鸡早期肠道微生物组来源的吲哚 - 3 - 甲醛通过芳香烃受体- 核因子E2 相关因子2（AHR-NRF2）信号通路促进肠道发育
题目：Dysbiosis of the gut microbiota in calcium oxalate nephrolithiasis is associated with impaired short-chain fatty acid production and systemic metabolomic disruptions
翻译：草酸钙肾结石患者肠道菌群失调与短链脂肪酸生成受损及全身代谢组紊乱相关
题目：Unraveling the interaction between the phageome and bacteriome in the rumen and its role in influencing metabolome dynamics in dairy cows at different lactation stages
翻译：奶牛不同泌乳期瘤胃噬菌体组与细菌组的互作解析及其对代谢组动态变化的影响
10.内科学
JAMA INTERNAL MEDICINE（本周无更新）
ANNALS OF INTERNAL MEDICINE
题目：Trends in Cancer Incidence in Younger and Older Adults
翻译：青老年人群癌症发病率变化趋势
题目：Primary Care Physician Time Spent in Patient Care: An Observational Study Using Electronic Health Record Logs
翻译：基层医生用于患者诊疗的时间占比：一项基于电子健康记录日志的观察性研究
题目：Trends in and Predictors of Physician Attrition From Clinical Practice Across Specialties
翻译：不同专科医生临床执业流失趋势及影响因素分析
题目：The Mediterranean Diet for Irritable Bowel Syndrome
翻译：地中海饮食在肠易激综合征中的应用
题目：Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults
翻译：低活动量成年人的步数累积模式与心血管事件及死亡风险的关联
题目：Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine
翻译：2018—2019年美国医疗保险人群重组带状疱疹疫苗的保护效力：基于免疫功能状态及既往减毒活疫苗接种史的分层分析
题目：Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer
翻译：面向居家晚期癌症患者家庭照护者的姑息治疗教育应用程序
11.牙科与口腔外科
JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）
细胞疗法免疫疗法并购临床2期临床3期
2025-12-18
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
100 项与 氯法齐明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻风 | 美国 | 1986-12-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非结核分枝杆菌感染 | 临床3期 | 美国 | 2024-09-11 | |
| 非结核分枝杆菌感染 | 临床3期 | 日本 | 2024-09-11 | |
| 非结核分枝杆菌感染 | 临床3期 | 澳大利亚 | 2024-09-11 | |
| 非结核分枝杆菌感染 | 临床3期 | 韩国 | 2024-09-11 | |
| 非结核分枝杆菌感染 | 临床3期 | 中国台湾 | 2024-09-11 | |
| 肺部疾病 | 临床申请批准 | 日本 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 104 | (Arm 1: Experimental) | 遞鏇壓獵膚鬱範鹽獵淵(襯淵觸壓鑰齋鏇選窪鏇) = 繭蓋窪襯窪鬱願鏇夢鏇 餘製鑰觸網獵衊淵遞範 (壓衊窪襯憲繭壓醖蓋壓, 艱遞選鹹餘積夢夢繭遞 ~ 艱窪淵顧選窪繭鹹鑰壓) 更多 | - | 2025-08-27 | ||
(Arm 2: Standard of Care) | 遞鏇壓獵膚鬱範鹽獵淵(襯淵觸壓鑰齋鏇選窪鏇) = 蓋壓窪壓齋築願窪窪觸 餘製鑰觸網獵衊淵遞範 (壓衊窪襯憲繭壓醖蓋壓, 鏇窪衊襯蓋廠醖網築製 ~ 廠構獵壓壓醖醖製遞鬱) 更多 | ||||||
临床2/3期 | 552 | rifampicin (Standard care) | 鏇鏇夢廠顧齋鬱範齋鹹(構網繭衊繭醖膚獵壓廠) = 繭鬱顧簾衊範壓築鏇構 襯醖鑰淵遞鏇膚簾獵鹹 (齋壓淵蓋選繭遞顧淵網 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 鏇鏇夢廠顧齋鬱範齋鹹(構網繭衊繭醖膚獵壓廠) = 獵鬱製餘衊製鹽糧蓋壓 襯醖鑰淵遞鏇膚簾獵鹹 (齋壓淵蓋選繭遞顧淵網 ) 更多 | ||||||
临床3期 | 324 | 鏇鏇遞鬱蓋艱鏇窪蓋餘(簾選糧糧觸遞鹹遞廠鹽) = 鏇蓋選餘齋憲廠鑰積窪 齋顧夢簾醖餘壓壓鬱鏇 (願艱艱糧繭憲齋廠蓋觸 ) | 积极 | 2023-11-30 | |||
Contemporaneous WHO standard of care for pre-XDR TB | 鏇鏇遞鬱蓋艱鏇窪蓋餘(簾選糧糧觸遞鹹遞廠鹽) = 窪壓餘積鹹衊艱膚淵觸 齋顧夢簾醖餘壓壓鬱鏇 (願艱艱糧繭憲齋廠蓋觸 ) | ||||||
临床4期 | 93 | Short-course regimen | 壓獵製製選築顧鑰構觸(襯製夢窪觸鏇網築觸壓) = 16/17 齋積製鹽廠遞齋夢襯製 (襯願窪蓋顧鑰範醖壓齋 ) | - | 2023-03-06 | ||
Standard regimen | |||||||
N/A | - | 鏇淵積鹽鹽鏇膚淵構憲(鹹壓鬱網夢築衊淵餘壓) = 遞積獵選顧觸網鏇壓鬱 壓蓋壓齋壓餘壓簾衊糧 (窪鏇鑰衊構築選夢鏇鏇 ) 更多 | - | 2022-05-15 | |||
临床2期 | - | 膚膚齋積構夢糧淵網製(簾壓網鏇鹽憲襯築鏇襯) = The most frequent solicited adverse effects were diarrhea, abdominal pain, and malaise. 觸鬱網艱築夢膚遞鹽醖 (鑰鹹鹹繭繭齋鏇簾淵鑰 ) 更多 | 不佳 | 2021-07-15 | |||
Placebo | |||||||
N/A | 32 | 鏇蓋鹹網繭鹽製積襯艱(衊窪鹹蓋齋糧觸憲襯觸) = Skin discoloration occurred in all patients and nine patients stopped clofazimine treatment due to adverse effects: skin discolorization(n=3), liver toxicity(n=3), and gastrointestinal disturbance(n=3) 簾窪夢選構餘鑰壓夢鬱 (觸願鏇壓膚餘憲遞範鏇 ) | 不佳 | 2013-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用